Prosight Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Prosight Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,112	Closed	-$1.5M	–	52
2020 Q4	$1.5M	Sell	12,112 -102,442	-89%	-$13.5M	0.69%	30
2020 Q3	$11.2M	Buy	114,554 +32,454	+40%	+$4.06M	5.31%	4
2020 Q2	$12.8M	Buy	82,100 +7,100	+9%	+$1.08M	5.5%	3
2020 Q1	$10.8M	Buy	75,000 +12,100	+19%	+$2.34M	5.06%	6
2019 Q4	$12.9M	Buy	62,900 +309	+0.5%	+$56.4K	5.65%	6
2019 Q3	$5.03M	Sell	62,591 -62,374	-50%	-$5.29M	2.79%	16
2019 Q2	$11.8M	Sell	124,965 -50,735	-29%	-$4.38M	5.94%	4
2019 Q1	$15M	Sell	175,700 -77,300	-31%	-$6.42M	6.57%	4
2018 Q4	$14.2M	Buy	253,000 +172,845	+216%	+$10.6M	7.33%	2
2018 Q3	$6.55M	Sell	80,155 -2,939	-4%	-$207K	3.65%	10
2018 Q2	$2.91M	Sell	83,094 -214,656	-72%	-$6.54M	2.13%	18
2018 Q1	$6.11M	Buy	297,750 +124,853	+72%	+$3.21M	3.83%	8
2017 Q4	$4.9M	Buy	+172,897	New	+$4.82M	3.6%	11

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Prosight Management's RETA Position: Q1 2021 in Review

Prosight Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2021, closing a stake of 12,112 shares — an estimated $1.5M sold.

Prosight Management first reported a position in RETA in Q4 2017 and held it in 13 quarters. The position peaked at $15M in Q1 2019. 201 funds tracked by Wall St. Rank hold RETA as of Q1 2021.

Prosight Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2021 after selling out during the quarter.
Prosight Management sold 12,112 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2021, an estimated $1.5M.
Prosight Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 13 quarters.
Prosight Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $15M in Q1 2019.
201 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2021.

Based on Prosight Management's 13F filing for Q1 2021, filed 14 May 2021.